<DOC>
	<DOCNO>NCT01354379</DOCNO>
	<brief_summary>The purpose study test safety immune response new intranasal vaccine influenza , call NB-1008 . The vaccine compose licensed vaccine normally give injection , call Fluzone , adjuvant ( additive help vaccine work well ) , call W805EC . In prior clinical study vaccine show promising result term well tolerate elicit mucosal systemic immune response administration dropper . In study NB-1008 administer dropper well nasal sprayer determine sprayer enhance immune response .</brief_summary>
	<brief_title>Safety Immunogenicity Study Inactivated Nasal Influenza Vaccine NB-1008 Administered Sprayer</brief_title>
	<detailed_description />
	<criteria>1 . Male female . 2 . Are 1849 year age , inclusive . 3 . If female , must nonpregnant confirmed negative serum pregnancy test conduct screen negative urine pregnancy test conduct site within 24 hour precede receipt vaccine . 4 . Females surgically sterile least one year postmenopausal agree use oral , implantable , transdermal injectable contraceptive another reliable form contraception approve Investigator minimum 30 day prior vaccination 3 month follow vaccination . 5 . Healthy , determine medical history , physical examination , vital sign , clinical laboratory examination . 6 . Comprehension study requirement , express availability require study period , ability attend schedule visit . 7 . Has give write informed consent participate study . 1 . Presence significant acute chronic , uncontrolled medical psychiatric illness ( institution new medical surgical treatment , significant dose alteration uncontrolled symptom drug toxicity within 3 month ) . Subjects history chronic cough , frequent sinus infection , sinusitis , allergic rhinitis , nasal polyp obstruction , include deviate septum significant enough obstruct nasal opening exclude . Subjects seasonal rhinitis may include 'season ' occur within 3 month vaccination date currently receive intranasal steroid . 2 . Receipt 220102011 influenza vaccine 2009 pandemic H1N1 influenza vaccine . 3 . Positive serology HIV1 HIV2 , HCV antibodies . 4 . Platelet count &lt; 150,000/mm3 . 5 . Positive urine drug screen . 6 . History aspiration , dysphagia , swallow disorder , stroke neurologic condition may predispose subject aspiration test article respiratory tract . 7 . History Bell 's palsy . 8 . Cancer treatment cancer , within 3 year . Subjects history cancer diseasefree without treatment 3 year eligible . Basal cell carcinoma ( BCC ) ( SCC ) allow , unless present near nose . 9 . Impaired immune responsiveness , regardless cause , include diabetes mellitus . 10 . Presently receive history receive medication treatment affect immune system immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) past 6 month . 11 . Chronic use inhale intranasal spray include decongestant corticosteroid . 12 . Presently smoker tobacco user history smoke tobacco use within past year prior screen . 13 . Receipt plan administration nonstudy vaccine within 30 day study , include license influenza vaccine prior Day 60 telephone contact . Immunization emergency basis Tetanus Toxoids Adsorbed adult use ( Td Tdap ) 8 day least 8 day dose study vaccine allow . Administration study vaccine delay nonstudy vaccine administer give soon acceptable , describe . 14 . Known allergy vaccine component , include egg , egg product , thimerosal . 15 . History allergic and/or anaphylactic type reaction inject vaccine component NB1008 [ soybean oil , dehydrate alcohol ( anhydrous ethanol ) , polysorbate ( Tween 80 ) cetylpyridinium chloride ( CPC ) ] . 16 . History drug chemical abuse year study . 17 . Receipt investigational product nonregistered drug within 30 day study entry currently enrol investigational drug study intend enroll study within ensue 6 month period . 18 . Use nasally administer prescription overthecounter ( OTC ) medication within 7 day vaccination 19 . Receipt blood blood product 8 week study entry plan administration prior Day 60 telephone contact . 20 . Donation blood blood product within 8 week study entry time Day 28 clinic visit . 21 . Acute disease within week prior vaccination , define presence moderate severe illness ( determined investigator medical history physical examination ) without fever . For subject minor illness , diarrhea , mild upper respiratory tract infection without lowgrade febrile illness , subject rescreened complexly recover . 22 . Any condition , opinion investigator , might interfere study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>